ReviewExpert review of anticancer therapy2012
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.
Review in Expert review of anticancer therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Clinicopathological Predictors of Recurrence in Uterine Sarcomas-A Narrative Review.Journal of clinical medicine · 2025Review
- Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.Cancer research communications · 2025Article
- In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Molecular cancer therapeutics · 2023Article
- HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.Cancers · 2023Review
- Uterine serous carcinoma.Gynecologic oncology · 2021Review
- Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences.American journal of cancer research · 2020Review
- Learning common and specific patterns from data of multiple interrelated biological scenarios with matrix factorization.Nucleic acids research · 2019Article
- PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.Frontiers in oncology · 2019Review
- Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.International journal of molecular sciences · 2018Review
- A rare case of endometrial cancer metastatic to the uveal choroid.Gynecologic oncology reports · 2018Article
- Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Improved i.p. drug delivery with bioadhesive nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Inferring pathway dysregulation in cancers from multiple types of omic data.Genome medicine · 2015Article
- Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- The emerging genomic landscape of endometrial cancer.Clinical chemistry · 2014Review
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.British journal of cancer · 2012Article
- Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Endometrial cancer (EC) is the most common female genital malignancy in the USA. Most carcinomas arising from the uterus are estrogen dependent and are associated with obesity and hypertension. They are designated type I ECs and typically, due to their early diagnosis secondary to postmenopausal bleeding, have a good prognosis. By contrast, type II ECs develop in older patients, are not hormone dependent and are responsible for most recurrences and deaths from EC. Uterine serous cancer constitutes up to 10% of all endometrial tumors, and represents the most biologically aggressive variant of type II EC. This article will describe the most salient molecular markers that have been identified in uterine serous cancer, thus far with emphasis on the use of erbB2 (HER2/neu) as the first of a series of therapeutic markers for the treatment of this highly-aggressive subset of ECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.